Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy.

Abstract

OBJECTIVE:

HBI-8000 (tucidinostat) is a novel, oral histone deacetylase inhibitor that selectivity inhibits Class I (histone deacetylase 1, 2, 3) and Class II (histone deacetylase 10) with direct anti-tumor activity through various mechanisms of action, including epigenetic reprogramming and immunomodulation. It has been approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.

METHODS:

This multicenter, prospective phase I dose-escalation trial evaluating the safety of twice weekly HBI-8000 was conducted in Japan. Eligible patients had non-Hodgkin's lymphoma and no available standard therapy. The primary endpoint was maximum tolerated dose; secondary endpoints included anti-tumor activity, safety and pharmacokinetics.

RESULTS:

Fourteen patients were enrolled in the study. Twelve patients were assessed for dose-limiting toxicity: six patients in the 30 mg BIW cohort had no dose-limiting toxicitys; two of six patients in the 40 mg BIW cohort had asymptomatic dose-limiting toxicitys. Treatment was well tolerated; adverse events were predominantly mild to moderate hematologic toxicities and were managed with dose modification and supportive care. Thirteen patients were included in the efficacy analysis. Objective response was seen in five of seven patients in the 40 mg BIW cohort; three partial responders had adult T-cell leukemia-lymphoma. In the 30 mg BIW cohort, three of six patients had stable disease after the first cycle.

CONCLUSIONS:

Treatment with HBI-8000 30 and 40 mg BIW were well-tolerated and safe, with hematological toxicities as expected from other studies of histone deacetylase inhibitor. The maximum tolerated dose and recommended dosage for phase II studies of HBI-8000 is 40 mg BIW. Preliminary efficacy results are encouraging.

• Authors: Makoto Yoshimitsu, Kiyoshi Ando, Takashi Ishida, Shinichiro Yoshida, Ilseung Choi, Michihiro Hidaka, Yasushi Takamatsu, Mireille Gillings, Gloria T Lee, Hiroshi Onogi, Kensei Tobinai
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 52 Issue 9 Pg. 1014-1020 (Sep 18 2022) ISSN: 1465-3621 [Electronic] England
• PMID: 35649345 (Publication Type: Journal Article, Multicenter Study)
• Copyright: © The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Aminopyridines
• Benzamides
• HBI-8000
• Histone Deacetylase Inhibitors
• Pyridines
• N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
• Histone Deacetylase 1
• Histone Deacetylases

Topics

• Adult
• Aminopyridines
• Benzamides
• Histone Deacetylase 1
• Histone Deacetylase Inhibitors (adverse effects)
• Histone Deacetylases
• Humans
• Japan
• Lymphoma, T-Cell, Peripheral
• Maximum Tolerated Dose
• Neoplasms
• Prospective Studies
• Pyridines